BSR_03_0053_A6_S70
— · A
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- A
- subtype
- A
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.550
- COMPLEMENT+0.390
- HEDGEHOG_SIGNALING+0.380
- INTERFERON_ALPHA_RESPONSE+0.380
- TGF_BETA_SIGNALING+0.380
- INFLAMMATORY_RESPONSE+0.350
- ALLOGRAFT_REJECTION+0.340
- COAGULATION+0.330
- NOTCH_SIGNALING+0.330
- PROTEIN_SECRETION+0.310
Top 10 suppressed
- MYC_TARGETS_V2-0.530
- E2F_TARGETS-0.410
- G2M_CHECKPOINT-0.360
- SPERMATOGENESIS-0.180
- UNFOLDED_PROTEIN_RESPONSE-0.170
- KRAS_SIGNALING_DN-0.150
- MYC_TARGETS_V1-0.150
- CHOLESTEROL_HOMEOSTASIS-0.070
- DNA_REPAIR-0.060
- MTORC1_SIGNALING-0.050
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_RRAEQZ97 | pilocytic astrocytoma | — | 0.884 |
| 2 | TCGA-64-5815-01A-01R-1628-07 | — | cohortA1 | 0.881 |
| 3 | BS_014EVM2D | low-grade glioma | — | 0.873 |
| 4 | TCGA-E2-A1L9-01A-11R-A13Q-07 | — | A | 0.870 |
| 5 | SRR5088824 | — | — | 0.868 |
| 6 | TCGA-46-3766-01A-01R-0980-07 | — | cohortSQ1 | 0.867 |
| 7 | TCGA-73-4658-01A-01R-1755-07 | — | cohortA1 | 0.866 |
| 8 | SRR8518191 | — | D | 0.863 |
| 9 | BS_ZZWMD6FA | Ganglioglioma | — | 0.862 |
| 10 | BS_JWSR581E | low-grade glioma | — | 0.860 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 38 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.550 | Inavolisib | — uncovered |
| COMPLEMENT | 0.390 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.380 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.380 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.380 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.350 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.340 | Idelalisib | — uncovered |
| COAGULATION | 0.330 | Binimetinib | — uncovered |
| NOTCH_SIGNALING | 0.330 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.310 | Remibrutinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.300 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.290 | Temsirolimus | — uncovered |
| APICAL_JUNCTION | 0.270 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.260 | Inavolisib | — uncovered |
| APOPTOSIS | 0.260 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.260 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.260 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.250 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.250 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.230 | Idelalisib | — uncovered |